Mitotech’s well-balanced management team includes experts in drug development, financial industry, fundamental biological research and start-up management. It is internationally diversified to reflect the reality of modern biotechnology industry trends and has been tested by years of intensive collaborative work.
CEO: Natalia Perekhvatova, MS, MBA
Ms. Perekhvatova has served as Chief Executive Officer/Chief Financial Officer of Mitotech since 2010. She was appointed as the CEO/CFO of Mitotech and became a member of the board of directors when the company started its drug development operations. Prior to that she acquired significant experience in financial industry working for Citigroup in London, UK. She started her career in 2000 and has been working in various marketing and business development roles in technology industries in Western Europe before joining Citigroup in 2006. She received her MBA degree from INSEAD and MS degree in Applied Mathematics with honors from the Moscow State University, Russia.
CCO: Lawrence Friedhoff, MD, PhD, FACP
Dr. Lawrence Friedhoff joined Mitotech in late 2010 as a Chief Clinical Officer and has been shaping company’s pre-clinical and clinical development programs in the U.S. and Europe since then. During his 25-year career in the pharmaceutical industry, he has managed the development of six new products all of which were approved by the FDA and often by many other regulators around the world. The annual sales of these new products total over $4 billion. His expertise covers planning and managing drug development from early preclinical stage to marketing approval. Before joining Mitotech, Dr. Friedhoff led clinical development at a variety of pharmaceutical and biotechnology companies including E.R. Squibb & Sons (later Bristol-Myers Squibb), Eisai (a Japan-headquartered pharmaceutical company) and Andrx Laboratories (NDA subsidiary of Andrx Corporation). His academic career includes positions at Cornell Graduate School of Medical Science and Sloan-Kettering Institute. Dr. Friedhoff holds MD degree from NYU School of Medicine and PhD degree from Columbia University.
CSO: Maxim Skulachev, PhD
As the CEO of Mitotech’s Russian holding company Mitotech LLC, Dr. Maxim Skulachev heads drug development in Russian and other Eastern-European markets and serves as the Chief Scientific Officer at Mitotech. He leads company’s drug discovery and drug optimization efforts across therapeutic areas in several countries and supervises drug sales and marketing efforts in Russia. Having multiple scientific teams under his supervision and collaborating with many more partner laboratories and scientific groups, Dr. Skulachev manages Mitotech’s fundamental research efforts that provide our company with valuable competitive advantage. His extensive academic career has originated from the Moscow State University, Russia, where he received his PhD degree in 1998.
COO: Anton Petrov, PhD, MBA
Dr. Anton Petrov has been working at Mitotech as its Chief Operating Officer since 2009. He has been supervising Mitotech’s Drug Development process in the U.S. and EU and coordinating International preclinical and clinical operations across Russia, EU and the U.S. He has been working in biotechnology industry since 2001, having held management positions at several biotech start-ups. His previous experience includes working at a biotechnology company in Los Angeles, CA, and founding his own innovative genetic diagnostics company in London, UK in 2006. He received his PhD degree from the University Of Southern California in the U.S. and obtained his MBA degree from INSEAD (France).